Clinical trial

Clinical Comprehensive Intervention on Cognitive Impairment of Schizophrenia Patients With Metabolic Syndrome

Name
20200815SMHC-sk-YChen
Description
This is a single-center, randomized, parallel-control study conducted in schizophrenic inpatients with metabolic syndrome who have been conducted with olanzapine. The purpose of this study is to evaluate the efficacy and safety of omega-3 polyunsaturated fatty acids, Xbox aerobic exercise and transcranial direct current stimulation( tDCS). Following a screening period, subjects who meet the entry criteria will be randomized to treated with omega-3 polyunsaturated fatty acids1.2mg per day, Xbox aerobic exercise 30min per day and tDCS at 2mA, 20 min(5 session/week) for 12 weeks.
Trial arms
Trial start
2020-10-01
Estimated PCD
2024-11-01
Trial end
2024-11-01
Phase
Early phase I
Treatment
Omega-3 polyunsaturated fatty acids
Omega-3 polyunsaturated fatty acids will be taken 1200mg per day plus on olanzapine.
Arms:
omega-3 polyunsaturated fatty acids
Xbox aerobic exercise
Patients will do Xbox aerobic exercise 30min per day plus on olanzapine.
Arms:
Xbox aerobic exercise
transcranial direct current stimulation,tDCS
Patients will receive tDCS at 2mA, 20 min for 5 session per week plus on olanzapine.
Arms:
transcranial direct current stimulation
Olanzapine
Patients will take only olanzapine pills.
Arms:
olanzapine
Size
120
Primary endpoint
Explore the treatment of cognitive impairment in schizophrenia patients with metabolic syndrome
from baseline to 3 months after treatment
Eligibility criteria
Inclusion Criteria: 1. Meets the Diagnostic and Statistical Manual of Mental Disorder,Fifth Edition(DSM-V) criteria for Schizophrenia. 2. Patients have got standard treatment of olanzapine monotherapy for more than 6 months, PANSS baseline ≤ 60. 3. Meets the ATP-III criteria for metabolic syndrome. 4. Male or female subjects aged 18-60 years, education level of junior high school for above. 5. The patient fully understand and signed the informed consent form. Exclusion Criteria: 1. Serious and instable body disease such as cerebrovascular disease, liver and kidney disease, disease of internal secretion (abnormal thyroid function), blood disease; any history of seizures or other organic brain diseases. 2. Pregnant or lactating women and women of childbearing potential throughout the study period; patients who have plans to move to other places within the year. 3. History of diabetes, hyperlipidemia and other metabolic abnormalities. 4. Due to other reasons, the researchers considered it unsuitable to participate in this clinical trial. -
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 120, 'type': 'ESTIMATED'}}
Updated at
2023-04-18

1 organization

1 product

1 drug

1 indication

Indication
Schizophrenia